<DOC>
	<DOCNO>NCT00862264</DOCNO>
	<brief_summary>Efficacy tolerability fix combination Beclomethasone Dipropionate /Formoterol patient mild moderate persistent asthma .</brief_summary>
	<brief_title>Efficacy Tolerability Beclomethasone Dipropionate/Formoterol Single Inhaler Patients With Mild Moderate Persistent Asthma</brief_title>
	<detailed_description>The purpose study evaluate efficacy tolerability Beclomethasone Dipropionate/Formoterol single inhaler twice daily regimen patient mild moderate persistent asthma . Patients randomise receive either Beclomethasone Dipropionate/ formoterol single inhaler ( total daily dose : BDP/FF 400/24 µg ) Beclomethasone CFC ( total daily dose : BDP 1000 µg ) 12 week treatment .</detailed_description>
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<mesh_term>Formoterol Fumarate</mesh_term>
	<criteria>Clinical diagnosis mild moderate persistent asthma ( accord GINA 2003 guideline ) FEV1 &gt; = 60 % &lt; = 85 % predict normal value Patients free LABA least one month screen already treat least two month ICS experience ( ) daily use SABAs 1 4 puff , ( ii ) and/or clinical symptom three time week prior inclusion A document positive response reversibility test Pregnant lactating female woman childbearing potential without efficient contraception Heavy smoker define smoke &gt; 10 pack year Evidence asthma exacerbation cause hospitalisation require treatment oral/parenteral corticosteroid evidence symptomatic airway infection 4 week prior inclusion ( 3 month slowrelease corticosteroid ) Seasonal asthma asthma occur episodic exposure allergen occupational chemical sensitizer Clinical significant unstable concomitant disease , include clinically significant laboratory abnormality Evidence asthma worsen week precede randomisation ( e.g PEF variability &gt; = 30 % 2 consecutive day , SABA use &gt; 8 puffs/day 2 consecutive day , nocturnal awakening due asthma symptom 3 consecutive day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>